Back

Combined sodium-glucose-transporters inhibitors (SGLT2i) and glucagon-like-peptide receptor agonist (GLP1ra) compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry

2 September 2024 (08:52 - 09:11)
Organised by: Logo
Congress Presentation Part of: Repurposing anti-diabetic pharmacotherapy: the new cure for all evils? Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor David Garcia Vega

Ourense University Hospital Complex, Ourense (Spain)

3 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on repurposing of diabetic medications: the new cure for all evils?
Associate Professor A. Navar (Dallas, US)
Slides Video
Presentation thumbnail
Impact of SGLT2 inhibitors on liver-related outcomes in patients with heart failure - a population-based study in HK
Ms H. Yang (Hong Kong, HK)
Abstract Slides Video
Presentation thumbnail
Risk of Incident colorectal carcinoma in patients with type 2 diabetes on SGLT-2 inhibitor users: a population-based cohort study
Doctor G. Jong (Taichung, TW)
Abstract Slides Video

Access the full session

Session thumbnail
Repurposing anti-diabetic pharmacotherapy: the new cure for all evils?
Video

The Event

Event poster

ESC Congress 2024

2 September 2024 08:52 CET
You may be interested in
thumbnail
Congress Presentation
Combined treatment with SGLT2i and GLP1ra compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry
thumbnail
Congress Presentation
Combined therapy of SGLT2i and GLP1ra reduces all-cause mortality in patients with type 2 diabetes with a higher impact on women
thumbnail
Congress Presentation
Combined therapy of SGLT2i and GLP1ra reduces all-cause mortality in diabetic patients with a higher impact on women

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources